24/7 Wall St. |
3 Biotech Stocks Could Be the Next Big Takeover Targets
24/7 Wall St. The multi-center, open-label, randomized study evaluated the safety and efficacy of Jakafi, in comparison to the best available therapy, in patients with PV who are resistant to or intolerant of hydroxyurea, dependent on phlebotomy for hematocrit ... |
from phlebotomy - Google News http://bit.ly/2c06HjH
No comments:
Post a Comment